BDF
ALXN

Balasa Dinverno & Foltz’s Alexion Pharmaceuticals ALXN Stock Holding History

Balasa Dinverno & Foltz’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,405
Closed -$442K – 347
2021
Q2 		$442K Buy
2,405
+446
+23% +$76.6K 0.03% 202
2021
Q1 		$300K Buy
+1,959
New +$303K 0.02% 242

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Balasa Dinverno & Foltz's ALXN Position: Q3 2021 in Review

Balasa Dinverno & Foltz sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,405 shares — an estimated $442K sold.

Balasa Dinverno & Foltz first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $442K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Balasa Dinverno & Foltz reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Balasa Dinverno & Foltz sold 2,405 Alexion Pharmaceuticals shares in Q3 2021, an estimated $442K.
  • Balasa Dinverno & Foltz first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Balasa Dinverno & Foltz's Alexion Pharmaceuticals position peaked at $442K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2021, filed 26 Oct 2021.